Remicade hauls MTP to full-year growth
This article was originally published in Scrip
Continued strong growth for Remicade (infliximab) meant group sales at Mitsubishi Tanabe Pharma (MTP) stayed in positive territory for the year to March 31st, but only just. Last year's general price revision in Japan and lower non-pharmaceutical sales both weighed heavily on the top line.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.